- The ECJ has ruled that payments pharmaceutical companies make to public health insurers, whether as discounts, contributions, or mandatory payments, are considered rebates that reduce the VAT taxable amount.
- These rulings apply even if the payments are not labeled as commercial discounts and regardless of whether invoices are issued, as long as documentation proves the payment.
- The principle was confirmed in multiple cases (Germany, Hungary, and Novo Nordisk in 2024), establishing that such payments lower the actual price received by the producer and thus the VAT base.
- The decisions ensure fiscal neutrality and proportionality, allowing pharmaceutical companies across the EU to reclaim VAT where appropriate.
Source: meridianglobalservices.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
Latest Posts in "European Union"
- EU Customs Reform: Data Hub, Trusted Traders and New Import Models
- Flashback on ECJ Cases C-409/98 (Mirror Group) – Tenant inducements are not exempt property letting
- Roadtrip through ECJ Cases – Focus on Place of Supply of Intra-Community Acquisitions – ”Triangulation” (Art. 42)
- Roadtrip through ECJ cases: Focus on Promotional activities/Discounts (Art. 79, 87, 90(1))
- EU and China Agree Trade Understandings on Tariffs, Hybrid Vehicles and Market Access
